Abstract:Our previous study found that 2-phenyl-4-quinolone (2-PQ) derivatives are antimitotic agents, and we adopted the drug design concept of scaffold hopping to replace the 2-aromatic ring of 2-PQs with a 4-aromatic ring, representing 4-phenyl-2-quinolones (4-PQs). The 4-PQ compounds, whose structural backbones also mimic analogs of podophyllotoxin (PPT), maybe a new class of anticancer drugs with simplified PPT structures. In addition, 4-PQs are a new generation of anticancer lead compounds as apoptosis stimulators. On the other hand, previous studies showed that 4-arylcoumarin derivatives with 5-, 6-, and 7-methoxy substitutions displayed remarkable anticancer activities. Therefore, we further synthesized a series of 5-, 6-, and 7-methoxy-substituted 4-PQ derivatives (19–32) by Knorr quinoline cyclization, and examined their anticancer effectiveness. Among these 4-PQs, compound 22 demonstrated excellent antiproliferative activities against the COLO205 cell line (50% inhibitory concentration (IC50) = 0.32 μM) and H460 cell line (IC50 = 0.89 μM). Furthermore, we utilized molecular docking studies to explain the possible anticancer mechanisms of these 4-PQs by the docking mode in the colchicine-binding pocket of the tubulin receptor. Consequently, we selected the candidate compounds 19, 20, 21, 22, 25, 27, and 28 to predict their absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles. Pharmacokinetics (PKs) indicated that these 4-PQs displayed good drug-likeness and bioavailability, and had no cardiotoxic side effects or carcinogenicity, but we detected risks of drug–drug interactions and AMES toxicity (mutagenic). However, structural modifications of these 4-PQs could improve their PK properties and reduce their side effects, and their promising anticancer activities attracted our attention for further studies.

Advances in Privileged Structure 4-Quinolones As Antitumor Agents Research

Recent Advances of Quinones As a Privileged Structure in Drug Discovery

Advances in Antitumor Research of CA-4 Analogs Carrying Quinoline Scaffold

Design, Synthesis, Structure-Activity Relationships and Mechanism of Action of New Quinoline Derivatives As Potential Antitumor Agents

In Vitro and in Silico Biological Studies of 4-Phenyl-2-quinolone (4-PQ) Derivatives As Anticancer Agents

Recent Advances in the Catalytic Synthesis of 4-Quinolones

Synthesis, structure-activity relationship, and biological evaluation of quinolines for development of anticancer agents.

Advances in Research on Antitumor Activities of Quinolines

8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential

Progress in the Synthesis of Quinolones as Antibacterial Agents

Design and Synthesis of 4(1H)-Quinolone Derivatives As Autophagy Inducing Agents by Targeting ATG5 Protein

Quinoline as a Privileged Structure: A Recent Update on Synthesis and Biological Activities

Synthesis of fluoroquinolone C-3 heterocycles, bis-oxadiazole methylsulfides and methiodides, and their antitumor activity

Synthesis, Molecular Modeling and Biological Evaluation of 2-Aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3h)-thione Quinolone Derivatives As Novel Anticancer Agent

Design, Synthesis and Antitumor Activity of 3-Substituted Quinolone Derivatives (I)

Recent advances in the study of structural modification and pharmacological activity of quinolones

The Association Between Anti-Tumor Potency and Structure-Activity of Protein-Kinases Inhibitors Based on Quinazoline Molecular Skeleton

Design and Synthesis of 2-(3-benzo[b]thienyl)-6,7-methylenedioxyquinolin-4-one Analogues As Potent Antitumor Agents That Inhibit Tubulin Assembly

Structure-activity relationships and antiproliferative effects of 1,2,3,4-4<i>H</i>-quinoxaline derivatives as tubulin polymerization inhibitors

Developing our knowledge of the quinolone scaffold and its value to anticancer drug design

Synthesis, Structure-Activity Relationships and Preliminary Mechanism of Action of Novel Water-Soluble 4-Quinolone-3-carboxamides As Antiproliferative Agents.